Beam Therapeutics(BEAM) - 2025 Q2 - Quarterly Results

Financial Performance - Beam Therapeutics ended Q2 2025 with $1.2 billion in cash, cash equivalents, and marketable securities, up from $850.7 million at the end of 2024[13]. - Research and Development (R&D) expenses for Q2 2025 were $101.8 million, compared to $87.0 million in Q2 2024, reflecting a 16.5% increase[13]. - The net loss for Q2 2025 was $102.3 million, or $1.00 per share, compared to a net loss of $91.1 million, or $1.11 per share, in Q2 2024[13]. - Beam's total assets increased to $1.39 billion as of June 30, 2025, compared to $1.10 billion at the end of 2024[18]. Clinical Trials and Developments - Beam has dosed 30 patients in the BEACON Phase 1/2 trial of BEAM-101, with the first adolescent patient also dosed, marking a significant milestone[10]. - In the BEAM-302 Phase 1/2 trial, 17 patients have been dosed, showing durable correction of the disease-causing mutation and restoration of AAT physiology[2]. - All doses tested in the BEAM-302 trial were well tolerated, with no serious adverse events reported, and treatment demonstrated a dose-dependent correction of the disease-causing mutation[6]. - Beam expects to provide a full program update for BEAM-302, including data from both parts of the trial, in early 2026[7]. - Beam plans to present updated data from the BEACON trial at the end of 2025 and initiate a Phase 1 healthy volunteer trial for BEAM-103 by the end of 2025[10]. Regulatory Approvals - The U.S. FDA granted orphan drug designation to both BEAM-101 and BEAM-302, supporting their development for rare diseases[10].